Business Wire

SMITHS-DETECTION

16.4.2024 08:01:30 CEST | Business Wire | Press release

Share
Smiths Detection launches cutting edge X-ray Diffraction scanner

Smiths Detection, a global leader in threat detection and security screening technologies, today announces that it has launched the SDX 10060 XDi, a ground-breaking X-ray scanner powered by diffraction technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415145550/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Smiths Detection's ground-breaking SDX 10060 XDi, powered by diffraction technology. (Photo: Business Wire)

X-ray Diffraction (XRD) is a powerful inspection technology offering highly accurate material discrimination and substance identification based on an object’s molecular structure. XRD is particularly suited to detecting constantly evolving compounds in powder, liquid or solid forms, such as ‘homemade’ explosives or narcotics, even for materials with similar densities.

Multi-level baggage and material handling operations and express forwarders are under pressure to screen huge volumes quickly and efficiently. The SDX 10060 XDi can transform this process by automating the resolution of potential explosive alarms, in turn improving both security and efficiency.

Due to its exceptional sensitivity, XRD technology can also be very effectively deployed to support customs agencies in screening for a range of contraband items including narcotics, helping to mitigate ever-growing threats to society.

Jerome de Chassey, President of Smiths Detection, commented: “We are immensely excited to announce the launch of the SDX 10060 XDi which marks a new era in security screening. Every minute of every day our threat detection and security screening technology helps to protect people and infrastructure, and this new development highlights our commitment to making the world a safer place. X-ray Diffraction will future-proof operations for a large variety of sectors, and we are proud to play a pivotal role in shaping the landscape of future threat detection.”

The SDX 10060 XDi can integrate seamlessly with existing material and baggage handling systems and is designed to meet ECAC Standard 3.1/3.2 and TSA 7.2 plus future regulations. Certification is underway.

See how XRD will enhance security here: https://youtu.be/CkoCpsrz97I

Jerome de Chassey, President, Richard Thompson, Vice President Marketing and Strategy, and Matthew Clark, Vice President Technology, will be present at Passenger Terminal Expo 2024 on 16 and 17 April, stand A145 in hall 5.1.

About Smiths Detection:

Smiths Detection is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence. With more than 70 years of field-tested experience, Smiths Detection deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals, biological agents, and narcotics – helping make the world a safer place.

For more information visit: http://www.smithsdetection.com/diffraction

About the SDX 10060 XDi:

The Smiths Detection SDX 10060 XDi leverages cutting-edge X-ray Diffraction (XRD) technology to offer unparalleled material discrimination and substance identification capabilities. By generating a unique 'diffraction fingerprint', it can accurately distinguish between substances with similar densities, making it exceptionally effective for identifying homemade explosives and narcotics in various forms. This advanced detection system is especially beneficial for high-volume, high-speed applications such as baggage screening at airports and parcel processing, where it enhances security and operational efficiency.

Discover how the SDX 10060 XDI can elevate your security screening operations here: https://www.smithsdetection.com/products/sdx-10060-xdi/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240415145550/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye